This is the Drug That Could Kick Regeneron's Stock Into Gear Post author:Sam Post published:December 13, 2017 Post category:BioPharma Regeneron shares have made little headway since the disappointing launch of Praluent in 2015. Source: BioSpace You Might Also Like Arcturus Rockets on New Hep B RNA Deal With Johnson & Johnson October 18, 2017 This Chicago Startup's Google Cardboard-Like Device Is Helping Athletes Diagnose Concussions May 18, 2017 Late-Stage Life Sciences Investment Firm, Aisling Capital, Closes $280M Fund November 1, 2017
This Chicago Startup's Google Cardboard-Like Device Is Helping Athletes Diagnose Concussions May 18, 2017